Unbound MEDLINE

Novel O-[(11)C]methylated derivatives of candesartan as angiotensin II AT(1) receptor imaging ligands: Radiosynthesis and ex vivo evaluation in rats. Bioorganic & medicinal chemistry [Bioorg Med Chem] Journal article

 
TitleNovel O-[(11)C]methylated derivatives of candesartan as angiotensin II AT(1) receptor imaging ligands: Radiosynthesis and ex vivo evaluation in rats.
Author(s)Hadizad T, Kirkpatrick SA, Mason S, Burns K, Beanlands RS, Dasilva JN 
InstitutionNational Cardiac PET Centre, Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Canada ON K1Y 4W7.
SourceBioorg Med Chem 2009 Oct 13.
Abstract[(11)C]Methyl-candesartan and its desethyl derivative ([(11)C]TH4) were developed as potential radiotracers for imaging angiotensin II (Ang II) type 1 (AT(1)) receptors. These compounds were synthesized via methylation of tetrazole-protected candesartan using [(11)C]methyl iodide followed by deprotection through HCl hydrolysis at 65 degrees C to produce [(11)C]methyl-candesartan, and 90 degrees C for [(11)C]TH4. Ex vivo biodistribution and competition studies were carried out for both [(11)C]methyl-candesartan and [(11)C]TH4 to assess tissue retention time course and binding selectivity. Besides the liver, [(11)C]methyl-candesartan and [(11)C]TH4 displayed highest tissue retention in the AT(1) receptor-rich renal cortex and outer medulla. At tracer doses 15min post-injection, [(11)C]methyl-candesartan demonstrated higher specific binding proportion for AT(1) receptors, and selectivity for AT(1) over Ang II AT(2), Mas, beta-adrenergic, and alpha(2)-adrenergic receptors in rat kidneys compared to [(11)C]TH4. This study indicates that [(11)C]methyl-candesartan has potential for in vivo imaging renal AT(1) receptors selectively using positron emission tomography.
LanguageENG
Pub Type(s)JOURNAL ARTICLE
PubMed ID19879152
  
Advertise on this site.